Essential Pharmaceuticals and Custodiol® HTK are Purchased by Accord Healthcare.

EWING, N.J., July 26, 2017 /PRNewswire/ -- Essential Pharmaceuticals, LLC formed in 2006 by founder and CEO, Allan Weber has been acquired by Accord Healthcare.  Custodiol ® HTK organ preservation solution, one of the top organ preservation solutions in the US Market, will now be distributed by Essential Pharmaceuticals LLC, a division of Accord Healthcare.  To focus on the bioprocessing market with its Ess line of products, Bio-Ess Laboratories has been formed with Mr. Weber as CEO and his team.

In 2016, after 5 years of research and development, Essential introduced its two newest products, Cell-Ess® for biopharmaceutical production and Clin-Ess® for Tissue preservation and transportation – collectively known as the "Ess" Products.  Both were developed internally and are manufactured and distributed by Essential Pharmaceuticals

Cell-Ess Universal Titer Boost and Enhancer increases monoclonal antibody titer in bio-processing while simultaneously improving protein quality.  Clin-Ess Tissue preservation and transport media is a unique tissue preservative that both preserves cellular function while causing less DNA and RNA degradation and fewer artifacts than using conventional methods.  This allows for more efficient and safer tissue preservation than traditional methods, and allows far more robust testing. 

To better focus on the unique customer and market needs of each of these product lines, it was decided that each business – Custodiol and the "Ess" products – would better serve their customers as independent entities.  In July of 2017, Bio-Ess Laboratories, LLC was spun out and is devoted entirely to the Ess products and their customers.  Said Mr. Weber, "the bioprocessing market is growing rapidly and will continue to grow for the foreseeable future.  The unique needs of these customers require a focused approach, which Bio-Ess will provide them.  Our unique products, coupled with our already reputable service, will allow pharmaceutical companies to increase productivity and returns."   Bio-Ess Laboratories will focus solely on these markets, again bringing the same outstanding team and service that these customers expect and deserve, with the same trusted team they know.  Our clients can expect renewed focus and investment from Bio-Ess into their market.

At time of Press Release – the Bio-Ess website had not been completed but it is expected to be launched by the end of this week.  The web address will be www.bio-ess.com.  The phone number remains the same at 1-844-ESS-PROD.

"We look forward to a promising future as Bio-Ess Labs," said Mr. Weber.

Media contact:

Denise Weber
[email protected] 
844-377-7763

SOURCE Bio-Ess Laboratories

Related Links

http://www.essentialpharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED